What the research found

Researchers examined nearly a decade of US national health data to understand how fasting insulin—a marker of insulin resistance—relates to death risk across different blood-sugar states. They compared three groups: people with normal glucose levels, those with pre-diabetes, and those already on diabetes medication.

The key finding was asymmetrical: in pre-diabetes, higher fasting insulin predicted substantially greater cardiovascular death risk. However, in people already treated for type 2 diabetes, the relationship reversed—higher insulin appeared protective. The authors interpret this counterintuitive result as a survivor bias: people who remain alive long enough to be studied despite poor insulin sensitivity likely represent a healthier subset. Notably, fasting insulin never normalized in treated diabetics, staying 1.6–2.3 times higher than healthy controls, even after years on medication. Early in diabetes treatment (first five years), insulin levels did decline modestly, then plateaued.

Why it matters for you

If you're tracking metabolic health without diagnosed diabetes, this reinforces that fasting insulin is worth monitoring. The pre-diabetes finding suggests that elevated fasting insulin—which you may see in your bloodwork even when glucose looks "acceptable"—carries real cardiovascular risk independent of blood sugar itself. Many standard protocols focus on glucose and HbA1c, but this work suggests fasting insulin deserves equal weight as an early warning signal.

For those already managing type 2 diabetes or using insulin-modulating therapies (GLP-1s, metformin, peptides affecting insulin secretion), the takeaway is more nuanced: the study doesn't argue for lowering insulin at all costs once diabetes is established. Instead, it highlights that insulin resistance—the core problem—persists despite medication. This may inform decisions about intensity of lifestyle intervention (strength training, caloric deficit, sleep consistency) or need for additional agents. The data also suggests that if your fasting insulin hasn't budged after five years of treatment, further intervention is unlikely to shift it through medication alone.

Caveats

• Observational study: cannot prove fasting insulin causes cardiovascular death; confounding variables may explain the associations.
• Survivor bias acknowledged: the protective effect of insulin in the diabetic group likely reflects that sicker, more insulin-resistant people have already died.
• No mechanistic data: the study measured associations, not how or why insulin links to heart risk.
• Treatment heterogeneity not detailed: "oral therapy" covers many different drug classes with different mechanisms; effects may vary.
• Single cross-sectional snapshot: baseline fasting insulin measured once; doesn't capture changes over time in individuals.